US Stock MarketDetailed Quotes
DCPH Deciphera Pharmaceuticals
- 14.110
- -0.510-3.49%
Trading Apr 25 10:29 ET
1.14BMarket Cap-6161P/E (TTM)
14.725High14.000Low42.61KVolume14.430Open14.620Pre Close603.04KTurnover0.10%Turnover RatioLossP/E (Static)80.80MShares17.73052wk High3.25P/B583.13MFloat Cap9.90052wk Low--Dividend TTM41.33MShs Float71.110Historical High--Div YieldTTM4.96%Amplitude6.510Historical Low14.151Avg Price1Lot Size
Deciphera Pharmaceuticals Stock Forum
Sign in to post a comment
THE UPDATE Mar 10
A review of Friday done on a Saturday and posted Sunday 🙄 I apologize. this started out to be a quick overview but turned into much, much more 😅. This is written over multiple sessions, so the style changes. Hang in there it may be worth the read 🤷 this turned out longer than I had planned, but my best ones often do 😉
Alright... I know, a complete bother. this iam guy 🔴 filling up Moomoo with his memes and junk 😆 so, what's more junk 🤷 I'll give this a go and see if moo all lik...
Alright... I know, a complete bother. this iam guy 🔴 filling up Moomoo with his memes and junk 😆 so, what's more junk 🤷 I'll give this a go and see if moo all lik...
68
31
The company's lower P/S ratio may be due to its poor revenue outlook. The market's expectation of continued weak revenue growth could impact share price. The weaker revenue result compared to industry growth may have led to shareholder pessimism and a depressed P/S ratio.
Insider selling showcases potential mistrust in Deciphera Pharmaceuticals' stock. Despite some buying, the overall transactions need careful monitoring before investing.
The recent significant sale of shares by the company's President at around the current price, combined with the fact that insiders own less than most companies, could possibly be seen as indicators of cautious sentiment towards the company's stock.
News
$Deciphera Pharmaceuticals(DCPH.US$ Company Announced Its Study of Patients With TGCT Met Its Primary and Secondary Endpoint
1
Deciphera Pharma's fast-growing revenue contrasts with steep share price decline, possibly due to concerns about balance sheet, cash position, and scalability. Underperforming stocks and long-term weakness may signal challenges.
ColumnsToday's Pre-Market Stock Movers: BMY, ADBE, MSTR, AZN and More
Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%,...
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%,...
10
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Taurus27 : Thank you for taking the efforts to share with us your thoughts. Do rest well .
101633546 : thanks for the UEC update!
TinkerB3ll : Rest well and enjoy the rest of the Sunday evening.
SL99 : 学到了很多，虽然对于图还是不太懂但是会努力慢慢学会看懂，非常感谢你的分享和所付出的时间
tpearly : Much love kind sir! Thank you for your thorough insights, poetry, images, and chart patients. I took a lot of screenshots to study on the desktop as I'm reading this on mobile. Like many others, we look forward to your insights. Christ bless you.
View more comments...